|
|
|
Zoekertjes
|
Zoekertje : [ Email de adverteerder ] [ Zoekertjes van deze Adverteerder ] - 90 keer bezocht
| Categorie : |
~Andere > ~Andere |
| Titel : |
Insomnia Treatment Market Size, Competitive Landscape 2029 (Aangeboden)
|
| Beschrijving : |
Global Insomnia Treatment Market is segmented By Treatment Type (Over the Counter Sleep Aids, Prescription Sleep Aids), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Share, Size, Outlook, and Opportunity Analysis, 2022-2029
Market Overview
During the projection period, the Global Insomnia Treatment Market is predicted to develop at a high CAGR of 5.2 percent (2022-2029).
Insomnia is a sleeping problem in which a person finds it difficult to fall or remain asleep. People with insomnia may be unsatisfied with their sleep and exhibit symptoms such as weariness, low energy, difficulty concentrating, mood swings, and poor work or school performance. Insomnia is a financial and public-health concern affecting up to one-third of the population of the United States.
Download Free Sample: https://datamintelligence/download-sample/insomnia-treatment-market
Market Trends
The expanding number of sleep disorders, reasonable reimbursement scenarios for pharmaceuticals given in insomnia therapy, rising health awareness leading to effective insomnia treatment, and developing healthcare infrastructure are all driving the worldwide insomnia treatment market forward.
The market will rise due to the development of new technologies and the launch of medical equipment. The development of new technologies and the introduction of medical gadgets are projected to enhance market growth. The major players in the market have a considerable influence on the market. The US Food and Drug Administration (FDA) recently approved Eisai Co. Ltd's in-house developed orexin receptor antagonist DAYVIGO (lemborexant) CIV for the treatment of adults with insomnia defined by sleep onset and/or sleep maintenance in adults the United States in June 2020.
Adults in 2020 reported their stress levels as 5.0 on a scale of 1 to 10, up from 4.9 in 2019, according to the American Psychological Association's (APA) Stress in America study. Furthermore, stress levels among Gen Z individuals have increased slightly over the last two years, ranging from 5.6 in 2018 to 5.8 in 2019 and 6.1 in 2020. Insomnia is typically connected with other disorders and seldom occurs on its own. There is currently a drive to define persistent insomnia as an illness that requires therapy, rather than addressing the primary disorder, when symptoms of insomnia may go unrecognised or untreated. Insomniacs are more likely to develop psychological illnesses like sadness and anxiety, according to research Increased healthcare consumption and expenditures, decreased quality of life, drug or alcohol abuse, poor occupational performance, and accidents are all factors to consider.
Moreover, throughout the projection period, the increase of psychiatric problems and constantly growing noise levels in metropolitan areas would boost the insomnia treatment market.
The market's expansion will be hampered by misconceptions about the seriousness of sleeplessness.
Misconceptions regarding the importance of insomnia, as well as patient non-adherence to therapy, are projected to limit market growth throughout the projection period.
COVID-19 Impact Assessment
The COVID-19 pandemic has wreaked havoc on people's lives. It has produced tremendous tension, anxiety, and concerns for many people about their health, social isolation, job, finances, and the struggle of managing work and family duties. A major life event like this is likely to interrupt sleep and have an effect on market growth. According to the American Academy of Sleep Medicine's (AASM) Sleep Prioritization Survey 2020, about a third of adults (33%) have noticed a change in sleep quality, 30% have noticed a change in their ability to fall asleep, and 29% have noticed a change in their nightly amount of sleep as a result of the COVID-19 pandemic.
Furthermore, ladies were more likely than males to say that the COVID-19 epidemic has affected their bedtimes (31%). (25%).
Furthermore, some people around the world became depressed as a result of the pandemic's fear. As a result, an increase in coronasomnia, stress, and depression linked to the COVID-19 pandemic boosts demand for insomnia medications and propels market expansion.
Analysis of Segments
During the projection period, the orexin antagonist segment is expected to develop at the quickest CAGR (2022-2029)
By suppressing the arousal system's wakefulness-promoting orexin neurons, orexin antagonist tablets aid in the natural transition from insomnia to sleep. Suvorexant helps people fall asleep faster and stay asleep longer. This unique option features a favourable permissibility profile and a low side-effect profile.
Suvorexant is a powerful dual orexin receptor antagonist that inhibits both OX1R and OX2R receptors. It promotes sleep by inhibiting the binding of orexin-A and B, wakefulness-promoting neuropeptides.
According to a study published in the Frontiers in Neuroscience in July 2020 titled Evolution of Orexin Neuropeptide System: Structure and Function, there are approximately 70,000 orexin neurons in the human brain's perifornical lateral hypothalamus that send signals throughout the brain and spinal cord. Suvorexant has a different mode of action than benzodiazepines and nonbenzodiazepines because it has no impact on Gamma-aminobutyric acid (GABA). It inactivates wakefulness rather than encouraging sleep. As a result, these factors will propel the segment forward over the forecast period.
Analyses by Location
The global insomnia treatment market is dominated by the North American area.
The insomnia treatment market is dominated by North America. Over the projected period, the market will be driven by the rising demand for sleep disorder treatment in the United States and Canada, as well as the rising prevalence of sleep disorders. According to the American Academy of Sleep Medicine 2020, stress can cause adjustment insomnia, which affects up to 20% of persons in the United States each year.
Behavioral insomnia, which affects 30% of children, is more frequent among children who have poor sleeping patterns. Prescription medicines, substance misuse, medical problems, and mental health conditions all contribute to insomnia, which affects roughly 3% of the population. Some of the particular causes include depression, drug withdrawal, obesity, and anaemia.
In addition, the availability of insomnia-specific support organisations in the country is a major driving force for the industry. The Canadian Sleep Society is one such national organisation dedicated to improving sleep for all Canadians via research, high-quality clinical care, professional and public education, and advocacy for sleep and sleep disorders medicine.
Competitive Environment
Insomnia treatment is a moderately competitive market with both local and worldwide players. Merck & Co., Ebb Therapeutics, Paratek Pharmaceuticals, Inc., Pfizer Inc., Sanofi S.A., Electromedical Products International Inc., Takeda Pharmaceutical Company Ltd., Cerêve Inc., Innovative Neurological Devices, Eisai, Co. Ltd., and others are some of the key players contributing to the market's growth. Product releases, acquisitions, and collaborations are among the leading players' growth tactics, all of which are contributing to the global growth of the Insomnia Treatment Market. Minerva Neurosciences Inc. and Royalty Pharma plc, for example, signed a deal in January 2021 under which Royalty Pharma will purchase Minerva's royalty interest in suvorexant. Seltorexant, a selective orexin 2 receptor antagonist, is now in Phase 3 testing for the treatment of MDD with insomnia symptoms.
Why should you buy the report?
• Visualize the global insomnia treatment market, segmented by treatment type, distribution channel, and region, with significant commercial assets and players highlighted.
• Analyse trends and co-development deals to identify commercial opportunities in the worldwide insomnia treatment market.
• Thousands of data points from the global insomnia treatment market segmentation at the 4/5 level in one Excel data sheet.
• After conducting extensive qualitative interviews and conducting an in-depth market investigation, a PDF report containing the most pertinent analysis was created.
• Product mapping in Excel for all major industry participants' key products
Audience You're After
• Buyers/Service Providers
• Investors in the industry/investment bankers
• Institutes of Education and Research
• Professionals in the field of research
• Emerging Businesses
• Manufacturers
About Us
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at DataM Intelligence
Email: infodatamintelligence
|
| Prijs : |
€ 308.448,00 (Nieuw) |
| Website : |
https://datamintelligence.com |
| Foto's - Min. 1 : |
|
|
Foto's - Min. 1 :
|
|
|
|
|
|
